Finance

Lists
Outlook: 77.8% bullish·0.0% bearish
Go to analysis
TMCI:NASDAQ
Treace Medical Concepts, Inc
$5.04
-0.49%
(-0.025) 1D
Nov 12, 10:07:37 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TMCI...
Open
$5.03
High
$5.12
Low
$4.81
Mkt. cap
330.09M
Avg. vol.
289.85K
Volume
11.49K
52-wk high
$5.25
52-wk low
$1.17
EPS
-$0.86
Beta
1.59
Shares outstanding
65.56M
No. of employees
450
Open
$5.03
High
$5.12
Low
$4.81
Mkt. cap
330.09M
Avg. vol.
289.85K
Volume
11.49K
52-wk high
$5.25
52-wk low
$1.17
EPS
-$0.86
Beta
1.59
Shares outstanding
65.56M
No. of employees
450
News stories
From web sources and news partners
Profile
Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions. In March 2021, Treace announced its intent to launch an initial public offering. Trading on the Nasdaq under the ticker symbol “TMCI”, Treace opened its IPO in April 2021. Wikipedia
About Treace Medical Concepts, Inc
CEO-
Employees450
Founded2014
Headquarters-
SectorHealth Care
IndustryMedical device
Websitetreace.com
Analyst ratings
Based on 1 analyst giving stock ratings to TMCI in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for TMCI in the last 3 months
Highest
Current $5.04
$6.50 (+29.10%)
Average
$6.50 (+29.10%)
Lowest
$6.50 (+29.10%)
Analyst
Recommendation
Action
Price target
Projected
Date
Rick Wise
Stifel Nicolaus
Buy
Upgraded
$6.50
+29.1%
11/09/2026
Ben Haynor
Lake Street
Buy
Reiterated
$7.00
+39%
08/10/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$5.00
-0.7%
08/10/2026
Danielle Antalffy
UBS
Hold
Maintained
$2.25
-55.3%
03/02/2026
Last report
Nov 6, 2026
Fiscal period
Q3 2026
-$0.15 / -$0.25
+39.80%beat
Revenue / Est. (USD)
48.25M / 47.71M
+1.14%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
62.52M
47.20M
45.38M
48.25M
Cost of goods sold
12.12M
9.79M
9.77M
9.90M
Cost of revenue
12.12M
9.79M
9.77M
9.90M
Research and development expenses
4.54M
4.62M
4.38M
4.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
51.78M
49.95M
46.19M
45.39M
Operating expense
56.32M
54.57M
50.56M
49.88M
Total operating expenses
68.44M
64.36M
60.33M
59.78M
Operating income
-5.92M
-17.17M
-14.96M
-11.53M
Other non operating income
88.00K
275.00K
202.00K
163.00K
EBT including unusual items
-9.39M
-17.96M
-15.87M
-12.57M
EBT excluding unusual items
-6.66M
-17.96M
-15.87M
-12.57M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.39M
-17.96M
-15.87M
-12.57M
Net profit margin
-15.03%
-38.05%
-34.98%
-26.04%
Earnings per share
-0.08
-0.12
-0.20
-0.15
Interest and investment income
527.00K
501.00K
445.00K
387.00K
Interest expense
-1.35M
-1.57M
-1.56M
-1.58M
Net interest expenses
-823.00K
-1.07M
-1.12M
-1.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.11M
-16.27M
-13.07M
-9.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps